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Abstract
Background: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a major complication for lupus patients, which
often leads to cognitive disturbances and memory loss and contributes to a significant patient morbidity and mortality. The
presence of anti-neuronal autoantibodies (aAbs) has been identified; as examples, anti-NMDA receptors and anti-Ribsomal P
aAbs have been linked to certain pathophysiological features of NPSLE.
Methods and Findings: In the current study, we used a proteomic approach to identify an intermediate neurofilament
alpha-internexin (INA) as a pathogenetically relevant autoantigen in NPSLE. The significance of this finding was then
validated in an expanded of a cohort of NPSLE patients (n=67) and controls (n=270) by demonstrating that high titers of
anti-INA aAb was found in both the serum and cerebrospinal fluid (CSF) of ,50% NPSLE. Subsequently, a murine model was
developed by INA immunization that resulted in pronounced cognitive dysfunction that mimicked features of NPSLE.
Histopathology in affected animals displayed cortical and hippocampal neuron apoptosis. In vitro studies further
demonstrated that anti-INA Ab mediated neuronal damage via inhibiting axonal elongation and eventually driving the cells
to apoptosis.
Conclusions: Taken together, this study identified a novel anti-neurofilament aAb in NPSLE, and established a hitherto
undescribed mechanism of aAb-mediated neuron damage that could have relevance to the pathophysiology of NPSLE.
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Introduction
Systemic lupus erythematosus (SLE) is the prototypic autoim-
mune disorder characterized by protean systemic manifestations
and the presence of a wide spectrum of autoantibodies (aAbs).
Currently, ,200 aAbs have been identified in SLE and the
number continues to grow [1–5]. However, only few of the aAbs
have demonstrated clinical significance or value as biomarkers to
facilitate diagnosis, disease activity assessment, disease phenotype
dissection or prediction of prognosis. Furthermore, even fewer
aAbs have established causal roles in the pathogenesis of SLE
[6–9]. Therefore, most of the SLE-related aAbs were interpreted
as the immune responses secondary to tissue injury and/or
represent quantitative amplification of natural aAbs secondary to
SLE polyclonal B cell activation [10–15].
Neuropsychiatric SLE (NPSLE) is a clinical feature of SLE
attended by cognitive dysfunction and memory loss that contributes
to significant patient morbidity and mortality [7,16–19].
The presence of anti-neuronal aAb has been known in SLE for
over 2 decades and several specific aAb potentially associated with
NPSLE have been identified [2,8,20–30]. A seminal study was
reported by Diamond and colleagues who demonstrated that a
subset of anti-dsDNA from SLE patients binds NR2 glutamate
receptors in the CNS [31,32], and found that these aAb mediated
cognitive impairment and emotional disturbances [33,34].
Recently, another important finding demonstrated that anti-
ribosomal P aAb could induce depression in mice via targeting a
novel neuronal surface protein causing calcium influx and
apoptosis [35,36]. These findings support the hypothesis that
certain aAbs against CNS autoantigens are pathogenic and
display different mechanisms that could help understand the
various NPSLE clinical phenotypes.
In the current study, we indentified the intermediate neurofil-
ament alpha-internexin (INA) as a target antigen in NPSLE by
using a proteomics approac\h. This finding was then validated in
an expanded of a cohort of NPSLE patients and controls showing
that significantly higher titers of aAb against INA are found in
both the serum and more importantly, the cerebrospinal fluid
(CSF) of NPSLE. Subsequently, a murine model was developed by
INA immunization that bears pronounced cognitive dysfunction
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cortical and hippocampal neuron apoptosis. In vitro studies
further demonstrated that anti-INA Ab could mediate neuronal
damage by inhibiting axonal elongation and driving the neurons to
apoptosis. Taken together, this study identified a novel anti-
neurofilament aAb in NPSLE, and established a hitherto
undescribed mechanism of aAb-mediated neuron damage that
could have relevance to the pathophysiology of NPSLE.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Review Board of
Renji Hospital. All subjects or their families gave written informed
consent. All experimental protocols were approved by the Animal
Care and Use Committee of Shanghai Jiao Tong University
School of Medicine, the approval numbers for this study is
2007126 and 2008078. The cerebellar tissue slides of non-human
primate were purchased from EUROIMMUN(BIOCHIP Mo-
saic
TM Cerebellum, Germany).
NPSLE Patients and Controls
Two hundred and fifty-six hospitalized patients admitted to the
Departments of Rheumatology, Neurology, or Emergency Med-
icine, Shanghai Renji Hospital from January 5, 2005 to December
26, 2008, were enrolled in the study. All SLE were diagnosed
according to the 1997 American College of Rheumatology (ACR)
revised classification criteria. NPSLE (n=67) was classified
according to the ACR nomenclature and case definitions
[16,37,38]. Control groups included (i) a separate group of SLE
(n=12) manifested as cerebral infarction (CI) with or without anti-
phospholipid aAbs; (ii) SLE that had developed septic meningitis
(n=22) where the diagnosis was established when a specific
bacterial or fungal pathogen was isolated in CSF; (iii) active SLE
without CNS involvement (n=85); (iv) rheumatoid arthritis
(n=30); (v) other neurological diseases (n=40); and (vi) healthy
donors (n=81) where hospital staff and medical students served as
normal controls. Serum samples from patients and healthy donors,
and totally 177 CSF samples from NPSLE and disease controls
were obtained. The characteristics of the study populations are
summarized in Table 1. The majority of the CSF samples have
been used in our published reports [39,40].
Animals
SD rats and C57BL/6 mice, all females, were purchased from
Shanghai SLAC Laboratory Animal Co. Ltd. Pregnant SD rats
were used for primary embryo neuron cell culture.
Protein preparation, 2-D electrophoresis,
immunoblotting and mass spectrometry
Brain and spinal cords were isolated from adult SD rats, and
protein was extracted by a commercial protein-extraction kit
(CALBIOCHEM Proteo Extract, 539779, Darmstadt, Germany).
2-DE was performed according to manufacturer’s instructions
(BIO-RAD, 163-2105, USA). After the electrophoresis, the gels
were stained with Coomassie brilliant blue or used for protein
transfer onto nitrocellulose membranes. Western blotting was
performed as described previously [24,26,27,41]. The serum
samples were diluted to 1:100 for immunoblotting the membranes
and the bound antibodies were visualized by 5-Bromo-4-chloro-3-
indolylphosphate/Nitroblue etrazolium (BCIP/NBT, CALBIO-
CHEM, 203790). The positive spot in the gel corresponding to the
one identified on the nitrocellulose membranes were isolated,
digested with trypsin and then subjected to MALDI-TOF MS
(Applied Biosystems, USA) operated in the reflectron-delayed
extraction mode (Central Research of Medical College of Fu Dan
University, Shanghai). The peptide mass data were searched
against the protein database SwissProt.
Antigen cloning and antibodies
A commercial plasmid (pReceiver-Z0330-B01, Fulengen, China)
containing an insert of the full length open reading frame of the
human INA gene was transduced into E. coli BL21-DE3 (Novagen,
Sweden), and the expressed recombinant protein was purified by
Ni2+ resin (20 mM Tris buffer, pH 10.0) (File S1). Rabbit anti-
human polyclonal antibodies to INA were generated by immuniz-
ing rabbits with recombinant INA (rINA), purified by protein A
and affinity chromatography, and a control IgG was prepared in
parallel (technical service provided by Chinese Academy of
Science). Monoclonal antibodies to INA (Chemicon, MAB 5224,
Table 1. Characteristics of the study population.
Groups
Gender:
M/F
Age: years
(Mean±SD)
Sera/CSF:
number Descriptions
*NPSLE 8/59 29.5611.6 67/60 Acute confusional state in 40 patients (22 complicated with seizure, 4 psychosis, 2 myelopathy, 2
seizure and psychosis, 2 seizure and myelopathy, 1 aseptic meningitis, 1 chorea, 1 myasthenia
gravis), isolated cognitive dysfunction in 6 (2 with headache), seizure in 6, psychosis in 3,
Demyelinating Syndrome in 2, movement disorder (chorea) and cranial neuropathy in 1, Guillain-
Barre ´ Syndrome in 1 and myelopathy in 7 patients.
SLE with Cerebral
Infarction(CI)
3/9 35.5612.1 12/10 6 with anti-phospholipid antibodies.
SLE Control 8/77 32.4610.4 85/28 Active SLE without CNS manifestation.
SLE with Septic
Meningitis
1/21 46.3611.2 0/22 Mycobacterium tuberculosis in 13, Cryptococcus neoformans in 9 patients.
Rheumatoid
Arthritis(RA)
4/26 36.7613.3 30/0 _
Neuro-disease 25/15 42.9614.5 0/40 cerebrovascular disease in 6, epilepsy in 2, migraine in 5, demyelinating disease in 4, spinal stenosis
in 1, leukodystrophy in 1, myelopathy in 2, mild head trauma in 3, and CNS infection in 16 patients.
Normal Control 21/60 39.3613.2 81/0 _
* All of the 67 NPSLE patients were evaluated by Glasgow or Mini Mental State Examination (MMSE) and showed conscious disturbance or a cognitive deficit.
doi:10.1371/journal.pone.0011124.t001
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IgG (KPL, 05-10-06, Gaithersburg, MD, USA), anti-caspase 3
antibody (Santa Cruz Biotechnology, sc-22140, CA, USA,
produced in Goat; and AbCam, ab13847, Cambridge, MA,
USA, produced in Rabbit), FITC-conjugated goat anti-rabbit IgG
(KPL, 02-15-06), TRITC-conjugated goat anti-mouse IgG (KPL,
03-18-09), TRITC-conjugated goat anti-Rabbit IgG (KPL, 03-15-
06) FITC-conjugated donkey anti-rabbit IgG (Jackson ImmunoR-
esearch, 711-095-152, West Grove, PA), TRITC-conjugated
donkey anti-goat IgG (Jackson ImmunoResearch, 705-025-003),
anti-His-tag polyclonal antibody (Cell Signaling, 2365, Danvers,
MA), were used in experiments.
Enzyme-linked immunosorbent assay (ELISA),
immunoblotting and indirect immunofluorescence
Fifty ml of purified rINA (2 mg/ml) was coated onto 96-well
micro-plates (Corning Costar, 9018, USA). After the plates were
blocked with 1% gelatin in PBS, sera diluted at 1:100, or undiluted
CSF were then added. The anti-INA pAb diluted at 1:10000 was
used as the positive control. In the immunoblotting assay, rINA
was subjected to 10% SDS-PAGE under reducing conditions and
transferred onto nitrocellulose membranes. After blocking, the
membrane was probed with serum (diluted from 1:200 to 1:1000)
and CSF (dilution of 1: 10 or 1:20). The ELISA and
immunoblotting assays were performed according to standardized
protocol. Mice, SD rats, monkey cerebral, spinal cord or cerebellar
tissue slides (EUROIMMUN, BIOCHIP Mosaic
TM Cerebellum,
Germany), and SD rat embryo neuron substrate coverslips were
used in indirect immunofluorescence study. Serum or CSF
samples were diluted to 1:100, or undiluted, respectively. The
anti-INA pAb diluted to 1:200 was used as the positive control.
Secondary antibodies were conjugated to either FITC or TRITC
as described above. In some experiments, serum was pre-
incubated and absorbed with rINA [42,43].
Immunization Protocol
Six to 8 week old female C57BL/6 mice were immunized
intraperitoneally (i.p.) with vehicle alone or 300 mg rINA, per
mouse, per immunization, in 100 ml of saline. The first
immunization was performed using Complete Freund’s Adjuvant
(CFA) (Sigma-Aldrich, F5581, St. Louis, USA). Four boosters were
given at bi-weekly intervals in Incomplete Freund’s Adjuvant (IFA)
(Sigma-Aldrich, F5506). To facilitate the increased permeability of
the blood-brain barrier, LPS (E. coli, 055:B5, Sigma), at a dose of
3 mg/kg diluted in lactated Ringers solution to 0.3 mg/ml, was
given as an i.p. injection twice, 48 hr apart at 8 weeks after the last
INA immunization. The histology, cognitive and behavioral
studies were performed at 1–2 weeks after the LPS treatment.
The experimental protocol was adapted from previous publica-
tions[31–33]. Animals were sacrificed after the cognitive test.
Figure 1. Identification of a-internexin (INA) as target antigen in NPSLE serum. The proteins extract from rat brain and spinal cord were
separated by 2-DE and stained with colloidal Coomassie blue (upper panels), or immunoblotted with NPSLE (lower left panel) or control (lower right
panel) sera. An immunoreactive spot at ,56 kDa/pI 5.2 was excised and subjected to MALDI-TOF MS. By searching the protein database SwissProt,
the peptide mass-mapping matched rat a-internexin (INA, alpha;a-INA; Rattus norvegicus, gi|9506811, kDa 56081.6, PI 5.2, protein score 99.99%). The
data is representative of 4 independent experiments.
doi:10.1371/journal.pone.0011124.g001
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An experimental group (INA immunized, LPS-treated, n=16)
and two control groups (normal, n=10 and INA immunized
alone, n=12) were studied. The studies included: the Morris water
maze (spatial learning and reference memory), open-field activity,
and beam-walking. The water maze task comprised two phases
and lasted for 5 consecutive days [44], which included a place
navigation test in the initial 4 days of testing and a probe trial on
day 5. The data were collected as described previously [45].
Immunohistochemical staining
Animals were sacrificed by deeply anesthetizing with sodium
pentobarbital (i.p., 40 mg/kg of body weight) and then transcar-
dially perfused with saline followed by a fixative containing 4%
paraformaldehyde and 0.05% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.4). For paraffin sections, the brains were removed,
post-fixed over 48 h in 4% paraformaldehyde, and then
embedded in paraffin. Coronal brain sections of hippocampal
and cortex tissue were cut at 5 um. The TUNEL assay for
apoptosis was carried out by using ApopTagH Plus Peroxidase In
Situ Apoptosis Detection Kit (Chemicon, S7101).
Primary cultures of cortical neurons
Cultures of pure cortical neurons were obtained from E16-17
embryos of SD rats as previously reported [46,47]. Single-cell
suspensions were collected and plated into cell culture plates pre-
coated with poly-L-lysine (Sigma-Aldrich, p2636) at a density of
0.5610
5 cells/well for a 96-well plate (for MTT reduction assay)
or 0.3610
5 cells/well for a 24-well chamber slide (for immuno-
cytochemisty), and cultured in Dulbecco’s minimum essential
medium (DMEM) containing 10% heat-inactivated fetal bovine
serum and 5% heat-inactivated horse serum at 37uCi na
humidified 5% CO2 incubator. After attachment, the medium
was replaced by serum-free Neurobasal medium supplemented
with 2% B27 and 2 mM glutamine (all purchased from Gibco,
Grand Island, NY). Neuronal cultures were subjected to various
concentrations of sterile anti-INA pAb or control IgG. The neurite
length assessment and cell viability was performed 24 or 96 hours
later. In some experiments, caspase-3 fmk Inhibitor Z-DEVD
(R&D, FMK004) at final working concentrations of 100 uM was
added to the cell culture.
Immunocytochemistry
The MTT (3(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide)(Sigma-Aldrich) assay was used to study the reduction
capacity of cortical neurons cultured in vitro as described previously
[46,47]. Survival of control group neurons was defined as 100%
and the treated groups were expressed as percent of control group
in MTT assay. Other cells were fixed with 4% paraformaldehyde,
blocked with 10% normal goat serum for 20 min, permeabilized
Figure 2. Anti-INA aAb in the sera and CSF of NPSLE. (A) Purified His-tagged recombinant human INA (66 kDa) was blotted with anti-His
antibody (lane 1), anti-INA pAb (lane 2), NPSLE serum probe at serial dilutions of 1:200, 1:400, 1:800, 1:1000 (lane 3–6), the same patient’s CSF diluted
in 1:10 and 1:20 (lane 7–8), another NPSLE serum probe and the patient’s CSF (lane 9–10), CSF from a SLE control and a neurological disease control
(lane 11–12). (B) SD rat primary neuron substrate stained with serum of normal donor (ND), anti-INA pAb, serum or CSF from SLE patients as indicated.
(C) NPSLE serum probe competitive inhibit anti-INA pAb staining. After pre-incubated with recombinant INA (rINA), the serum probe lost its
cytoplasmic staining.
doi:10.1371/journal.pone.0011124.g002
Anti-INA Autoantibody in NPSLE
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11124Anti-INA Autoantibody in NPSLE
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11124with 0.2% Triton X-100 for 10 min, and then washed three times
with 0.01 mM PBS. Monoclonal antibody against INA, anti-
caspase 3 antibody, Hoechst 33342 to stain nuclei (Sigma-Aldrich,
B 2261), and then secondary antibodies were applied in cell
staining. Some cultures were stained with secondary antibody
alone. The coverslips were rinsed and mounted with Gel/Mount
aqueous anti-fade mounting media (Biomeda Corp). The results of
immunostaining were examined with an Olympus BX 60
microscope or confocal laser scanning microscope (ZEISS LSM
510 META). Image-Pro Plus software was used to allow
quantitative analysis. The longest neurite from each single cell of
different groups was measured at 24 h after pAb treatment. 200
cells from each preparation were randomly selected and each
experiment was performed in triplicate cover slips, more than 600
cells of each cell group per experiment were measured.
Statistical analysis
Data were expressed as mean6S.E.M. Student’s t-test,
ANOVAs with repeated measures, and one-way ANOVA
followed by post hoc Dunnett’s t-test were used for statistical
evaluation of differences between groups. An alpha level of 0.05
was used as the criterion for significance.
Results
Identification of the 56 kDa internexin as target
autoantigen in NPSLE
Our studies began by utilizing the brain or spinal cord tissue
sections from mice, rat, and monkey as substrates for screening
anti-neuronal aAbs in the sera of NPSLE patients by indirect
immunofluorescence. Four NPSLE sera (two patients with severe
cerebralitis and myelitis, one with seizures, one with psychosis)
were identified by their reactivity to all species (Figure S1). All sera
probes are ANA positive without cytoplasmic staining against
Hep2 cells, and neither have anti-ribsomal P antibodies. Brain and
spinal cord proteins of the Sprague-Dawley (SD) rat were
extracted, then resolved by 2-dimention electrophoresis (2-DE)
and immunoblotted with these four sera, all of which recognized a
protein spot at 56 kDa/pI 5.2 (Figure 1). The spot was excised
from the gel, cleaved with trypsin, and subjected to matrix-assisted
laser desorption ionization time of flight mass spectrometry
(MALDI-TOF MS). The determined peptide mass data with the
highest score matched rat a-internexin (INA) (SwissProt accession
no. Theoretical Mr =56115.6 and pI =5.20). BLAST analysis
revealed that INA is highly conserved from rodents to Homo
sapiens (91–94% homology) [48–50]. Of note, it has been reported
that there is no cross antigenicity of INA with other neurofilament
proteins [51,52].
Anti-INA is a novel aAb in the sera and CSF of NPSLE and
the CSF anti-INA levels correlate with cognitive
impairment
To confirm that anti-INA aAbs are found in the sera of NPSLE
patients, purified His-tagged recombinant human INA was used
in a western blot. As expected, sera probes have a dose-
dependent reactivity to INA as opposed to control samples
(Figure 2A). Of note, anti-INA aAb was also detected in 3 of 4
CSF from the probe NPSLE. In a parallel indirect immunoflu-
orescence assay, anti-INA positive serum/CSF probes from
NPSLE reacted with primary cultured rat cortical neurons, with
a distinctive cytoplasmic and neurite staining pattern compared
to a faint anti-nuclear staining pattern from control SLE samples
(Figure 2B). Anti-INA polyclonal antibody (pAb) obtained from
rabbit showed a similar staining pattern as the probes, and when
double-stained with the probe, a co-localization and competitive
effect can be observed under fluorescent microscope. Finally, pre-
incubated with INA, the probes lost their cytoplasmic staining to
neurons (Figure 2C).
After the thorough confirmation of the existence of anti-INA
aAb in NPSLE, a further validation ELISA was carried out in a
cohort of patients (Figure 3A). We tested for anti-INA aAbs in the
sera of NPSLE (n=67), SLE manifested as cerebral infarction (CI)
with or without aPL aAbs (n=12), active SLE without CNS
involvement (n=85), rheumatoid arthritis (RA) patients (n=30)
and normal controls (n=81), and the positive anti-INA Ab rates in
sera among aforementioned groups were 52.2% (35/67), 33.3%
(4/12), 18.8% (16/85), 13.3% (5/30) and 1.2% (1/81), respec-
tively. The different frequencies of anti-INA Ab between NPSLE
group and other control groups was statistically significant
(p,0.001). More importantly, the OD of anti-INA Ab in CSF of
NPSLE patients was significant higher than that of SLE-CI, SLE
controls and neurological diseases controls. At a cutoff value
determined by the average OD of SLE controls plus 2SD, the rates
of positive anti-INA in CSF of NPSLE (n=60), SLE-CI (n=12),
SLE controls (n=28), neurological disease controls (n=40) were
41.7% (25/60), 0% (0/12), 7.1% (2/28), 10% (4/40), respectively.
Unexpectedly, 40.9% (9/22) SLE with CNS infections also had
detectable anti-INA Ab in CSF. Nevertheless, longitudinal analysis
of both sera and CSF among 17 NPSLE patients showed that the
levels of anti-INA Ab significantly declined after initiation of
therapy and eventual clinical remission (Figure 3B). The titer of
the Ab was inversely correlated with the cognitive status as
measured by Glasgow coma scale or Mini Mental State
Examination (MMSE) in the NPSLE patients who had anti-INA
Abs in their CSF (Figure 3C).
Mice immunized with INA plus LPS display cognitive
impairments that mimic NPSLE
A key question was whether anti-INA Abs are pathogenic or
merely a coincidental phenomenon. To address this question, a
murine model was established in order to assess the in vivo effects
of anti-INA on CNS (Figure 4A). Briefly, all mice immunized
with INA developed high titer anti-INA Abs 8–9 weeks after
immunization (data not shown). Only the mice immunized with
INA plus LPS, which facilitates increasing the permeability of the
blood-brain barrier (BBB), displayed distinctive learning and
memory deficits on tasks that depend on the integrity of the
hippocampus and cortex as gauged by Morris water maze test
(Figure 4B). The time latency for the mice finding a submerged
hidden platform in the water maze remained prolonged over the
4 days of training in the INA+LPS group (Figure 4C). In
addition, when the platform was removed at day 5, the control
groups of mice spent more time and effort in the quadrant where
the previous platform placed, as opposed to the INA+LPS group
thus suggesting a significant memory impairment (Figure 4D).
This impairment in learning and memory function is consistent
Figure 3. Anti-INA aAb in the sera and CSF is correlated with NPSLE activity. (A) Anti-INA aAbs in sera or CSF were determined by ELISA.
SLE-CI = SLE with cerebral infarction. (B) Dynamic changes anti-INA Ab levels in the sera or CSF from NPSLE patients before and after induction
therapy which lead to clinical remission. (C) The NPSLE patients who have positive anti-INA Abs in CSF, the titer of the Ab was inversely correlated
with the cognitive status as measured by Glasgow coma scale or MMSE.
doi:10.1371/journal.pone.0011124.g003
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which demonstrate poor performance in spatial memory tasks
[53–57]. Other profound neurological dysfunction, such as
exploratory behavior and motor coordination, was also observed
in INA+LPS mice in open field activity and beam walking tasks
(Figure S2).
INA immunized and LPS treated mice exhibited
hippocampal and cortical neuron apoptosis
As evidence that anti-INA Ab indeed penetrated the BBB and
gained access to its cognate CNS targets, it was observed that
there was IgG staining of the choroid plexus in INA+LPS
treated mice (Figure 5A). The effects of anti-INA penetration
can be appreciated as prominent diffuse hippocampal (CA1,
CA3 and dentate gyrus regions) and cortical neuron apoptosis as
gauged by TUNEL staining in INA+LPS treated mice, but not
in mice immunized with INA alone or in sham controls
(Figure 5B).
The anti-INA pAb inhibit the growth of neurites and
result in neuron apoptosis in vitro
To determine whether there is a pathogenic effect of anti-INA
Ab on neurons, rat embryo cortical neurons were subjected to
anti-INA pAb or control IgG. After 96 h of culture, cells exposed
to anti-INA pAb displayed a significant neurotoxicity as gauged by
impeded axonal outgrowth and cell viability (TUNEL staining)
(Figure 6A). Of note, anti-INA pAb, but not control IgG, could
penetrate the cells as demonstrated by directly secondary antibody
staining. As an intermediate neurofilament component, the
normal staining pattern of INA by an anti-INA monoclonal Ab
(mAb) was characterized within the cytoplasm of the cells and also
in the cell processes (Figure 6B, also seen in Figure 2B–C).
Seemingly related to these observations, it was noted that cells
treated with anti-INA pAb sequestrated INA in a cytoplasmic
compartment surrounding the nuclei.
The neurotoxic effect of anti-INA pAb could be appreciated
as early as the 24
th hour of culture. Quantitative measurement
Figure 4. Mice immunized with INA plus LPS display cognitive impairments. (A) Immunization protocol in C57 mice. Normal control
(n=10), INA immunized (n=12), INA+LPS treated (n=16). (B) Morris water maze test. Representative swimming traces of mice from different groups
on the third training day. The hidden platform is located in quadrant II. (C) The time latency to find the hidden platform in different groups of mice
during consecutive 4 training days. (D) The platform was removed at day 5, and the time (left) and efforts (right) mice spent in the quadrant where
the previous platform placed were calculated. All data were presented as mean6S.E.M.
doi:10.1371/journal.pone.0011124.g004
Figure 5. INA immunized plus LPS treated mice exhibited hippocampus and cortex neuron apoptosis. (A) IgG deposition at the choroid
plexus (left) and hippocampus (right) in different groups of mice. (B) CA1, CA3 and dentate gyrus regions of hippocampal, and cortex areas from
indicated group of mice. TUNEL staining demonstrated neuron apoptosis. (6400, Bar =50 mm; 6100, Bar =200 mm).
doi:10.1371/journal.pone.0011124.g005
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after 24 h exposure of anti-INA pAb (Figure 6C). In parallel, the
MTT assay showed that anti-INA pAb impaired neuron viability
in a dose-dependent manner (Figure 6D). Furthermore, the anti-
INA pAb-induced neuron apoptosis process was detected by
Caspase-3 activation. The perfectly overlapped co-localization of
Caspase-3 and INA in the cytoplasm indicated a possible link
between those two molecules. Interestingly, when Caspase-3 was
blocked by a specific inhibitor, the neurite outgrowth was still
impeded by anti-INA pAb, which suggested that apoptosis is the
downstream effect of anti-INA mediated neuron damage
(Figure 7).
Figure 6. The anti-INA pAb inhibit the growth of neurites and result in neuron apoptosis in vitro. (A) Primary rat embryo neurons were
co-cultured with medium, sterile anti-INA pAb (1:50), or control IgG for 96 hrs. The neurite outgrowth and cell viability was observed by light
microscopy. Apoptotic cells were detected by TUNEL assay. (B) A monoclonal antibody (Mab 5224) against INA was used for displaying INA location.
The TRITC goat anti-rabbit secondary antibody staining was to demonstrate the internalization of co-cultured Abs during the neuron cell growth.
(Bar =25 mm) (C) Quantitative measurement of cultured neurons axonal length at 24 hrs. (D) Viability of primary cultured neurons subject to
indicated concentrations of anti-INA pAb or control IgG after 24 h. The percentage of cell survival normalized to control cells was applied in MTT
assay. Data are represented as mean6SEM of three independent experiments.
doi:10.1371/journal.pone.0011124.g006
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In the current study, alpha-internexin was identified as a new
target autoantigen for NPSLE, in that the anti-INA aAbs in the
sera of NPSLE patients are significantly increased in ,50% of
NPSLE sera. More importantly, even by using SLE control values
(mean62SD) as cut-off, anti-INA Ab is still positive in .40% of
the CSF of NPSLE, which indicated a strong association between
this aAb and an intrathecal autoimmune processes. In addition,
the titer of anti-INA, both in the serum and CSF was correlated
with disease activity, further suggesting its potential usefulness as a
biomarker in NPSLE. However, its specificity and clinical value
may have limitations as evidenced by a similar positive rate in the
CSF of SLE patients with CNS infections [58–60]. It is noteworthy
that the pathogenesis of NPSLE is likely multi-factorial and that
antibodies to other targets may work independently or in concert
to produce the various NPSLE clinical phenotypes.
INA is a constitutional intermediate neurofilament (IF) protein
first described in 1985 [61].
In the mammalian nervous system, three types of IF proteins are
expressed in differentiated neurons, which include light (NF-L),
medium (NF-M), heavy (NF-H) neurofilament triplet proteins
(NFTPs). INA is expressed abundantly to form the group of type
IV IF throughout the development of the peripheral and central
nervous system, and is restricted to the central nervous system in
the adulthood [62–65]. Neuro-cytoskeletal filament proteins
ingeneral [59,60], or their components such as glial fibrillary acid
protein [3], microtubule associated protein-2 [27,66], and more
recently, INA have been described as potential target autoantigens
in SLE[58]. However, due to lack of sufficient validation and CSF
aAb analyses in the aforementioned studies, aAbs against
neurofilament proteins in NPSLE have been considered somewhat
insignificant [67].
Our data not only demonstrated a link between anti-INA aAbs
and NPSLE, but also took one step further to illustrate a direct
neurotoxic effect of this aAb. A murine model displayed anti-INA
access to its target protein when the permeability of the BBB was
interrupted by LPS, resulting in profound cortical and hippocam-
pal dependent cognitive impairment/memory loss. A plausible
mechanistic explanation of the pathological NPSLE phenotype
was supported by the observations that anti-INA Ab could inhibit
neurite outgrowth and axonal elongation, and subsequently
induced neuron apoptosis both in vivo and ex vivo.
It is known that, in adult CNS, INA is selectively expressed in
the gray and underlying white matter, such as neuron cell bodies
and processes of cortical layer II neuron, CA1 subfield and granule
neurons of the dentate gyrus of hippocampus, cerebellar granule
cells, and thin-caliber parallel fibers, as well as in the basal ganglia,
thalamus, midbrain, pons and gray matter of the spinal cord
[52,61,65,68–72]. The functions of INA include a scaffold for IF
formation and regulating the expression of other neurofilaments
during neuronal development, and it can self-assemble into
homopolymers or coassemble with other IF proteins to form
NFTPs in mature neurons [64,65,68,69,73–76]. The contribution
of INA to cytoskeletal integrity is important for axonal calibre and
nerve conduction speed, and INA plays an important role in
facilitating the neurite outgrowth [64,68,77–79]. Of potential
relevance to our findings, it is well established that abnormal
Figure 7. Apoptosis with caspase-3 activation is the downstream effect of anti-INA mediated neuron damage. Primary rat cortical
neurons were co-cultured with anti-INA pAb or control IgG for 24 h. Caspase-3 inhibitor was added as indicated. The cells were triple-labeled Hoechst
(blue), caspase-3 (red), and INA (green). (Scale bar =10 mm).
doi:10.1371/journal.pone.0011124.g007
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hallmark of many human neurodegenerative disorders including
amyotrophic lateral sclerosis, dementia with Lewy bodies, and
Parkinson disease.More specifically, INA along with other NF
proteins, are found to form pathological inclusions in a newly
defined neuronal intermediate filament inclusion disease (NIFID),
which presented as progressive early-onset dementia, pyramidal,
and extrapyramidal dysfunctions [72,80]. Studies with transgenic
mice overexpressing IF proteins, including INA, provide evidence
that dis-organization of the IF network can cause neurofilament
misaccumulation, progressive neurodegeneration, and ultimate
loss of neurons [73]. The findings that genetically modified mice
for IF successfully mimic certain degenerative neuropathological
phenotype [81]. It was also found that overexpression of INA in
PC12 cells induced apoptosis-like cell death [78]. Taken together,
these data support our observations that anti-INA Ab may
interfere with the location and function of INA, which in turn
contribute to neuronal damage.
Nevertheless, the precise mechanism of anti-INA mediated
neuron damage remains unclear. Previous studies suggested that
aAb induced neuronal death can occur without complement
activation or Fc receptor engagement, and demonstrated that
aAbs can alter behavior without causing inflammation in the CNS
[32–35]. The role of aAb directed against NFTPs or their
individual subunits in certain neurodegenerative conditions has
also been implicated [82]. Although according to previous
literatures that autoantibodies have been shown to penetrate
various living cells, how anti-INA internalize into neurons and
gain access to target proteins is still not known [83–86]. The
possibilities of that it is LPS alters the localization of INA or allows
anti-INA into cells can not be excluded, in addition, there may be
another cross reactivity exists which plays a role in the anti-INA
internalization process. Another key question needs to be
answered is that how anti-INA Ab inhibits neurite outgrowth
and drives the neuron to programmed death. A plausible
explanation would be a two step process according to our data.
First, anti-INA binds to INA, therefore interfere INA assembly/
coassembly for neurofilament transportation, which result in INA
accumulation and failure of axonal elongation. Subsequently,
caspase 3 dependent apoptosis is activated due to neuron
cytoskeleton ‘‘strangulation’’ [87,88]. Further investigations are
required to address these questions.
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Figure S1 Screening anti-neuronal aAbs in the sera/CSF of
NPSLE and SLE control patients by indirect immunofluorescence.
NPSLE serum from a patients with severe cerebralitis and myelitis
was identified by its reactivity to all species. All sera/CSF of SLE
probes are ANA positive without cytoplasmic staining against
Hep2 cells, and neither have anti-ribsomal P antibodies. Scale
bar =50 mm.
Found at: doi:10.1371/journal.pone.0011124.s002 (2.09 MB TIF)
Figure S2 An experimental group (INA immunized, LPS-
treated, n=16) and two control groups (normal, n=10 and INA
immunized alone, n=12) were studied. Neurological dysfunctions
including exploratory behavior and motor coordination, was
observed in INA+LPS mice in open field activity and beam
walking tasks.
Found at: doi:10.1371/journal.pone.0011124.s003 (0.20 MB TIF)
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